Profile data is unavailable for this security.
About the company
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
- Revenue in USD (TTM)2.82m
- Net income in USD-28.87m
- Incorporated2005
- Employees23.00
- LocationDare Bioscience Inc3655 Nobel Dr Ste 260SAN DIEGO 92122-1050United StatesUSA
- Phone+1 (858) 926-7655
- Fax+1 (302) 636-5454
- Websitehttps://www.darebioscience.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Benson Hill Inc | 359.83m | -132.72m | 39.54m | 270.00 | -- | 0.5875 | -- | 0.1099 | -0.7033 | -0.7082 | 1.90 | 0.3174 | 1.13 | 9.80 | 20.67 | 1,332,689.00 | -41.85 | -- | -49.16 | -- | 5.38 | 3.18 | -36.88 | -40.73 | 2.02 | -2.12 | 0.183 | -- | 24.16 | 156.43 | -11.58 | -- | 63.78 | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -16.05m | 39.77m | 4.00 | -- | 6.59 | -- | -- | -1.17 | -1.17 | 0.00 | 0.3807 | 0.00 | -- | -- | 0.00 | -194.65 | -- | -283.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.55 | -- | -- | -- |
| Xilio Therapeutics Inc | 0.00 | -70.96m | 39.87m | 73.00 | -- | 1.45 | -- | -- | -2.57 | -2.57 | 0.00 | 0.7474 | 0.00 | -- | -- | 0.00 | -73.11 | -- | -96.98 | -- | -- | -- | -- | -- | -- | -144.29 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| Natural Alternatives International, Inc. | 120.20m | -3.31m | 40.00m | 317.00 | -- | 0.4756 | 29.80 | 0.3327 | -0.5646 | -0.5646 | 20.53 | 13.56 | 0.8091 | 3.63 | 12.77 | 379,183.00 | -2.23 | 4.90 | -2.56 | 5.93 | 8.85 | 15.98 | -2.75 | 3.80 | 2.44 | -2.71 | 0.0996 | 0.00 | -9.91 | 3.06 | -76.46 | -20.74 | 27.08 | -- |
| NRX Pharmaceuticals Inc | 0.00 | -25.65m | 40.77m | 2.00 | -- | -- | -- | -- | -2.06 | -2.06 | 0.00 | -1.54 | 0.00 | -- | -- | -- | -200.56 | -120.57 | -- | -168.40 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 24.14 | -- | -- | -- |
| Reviva Pharmaceuticals Holdings, Inc. | 0.00 | -40.09m | 40.85m | 15.00 | -- | -- | -- | -- | -1.60 | -1.60 | 0.00 | -0.0482 | 0.00 | -- | -- | 0.00 | -303.75 | -- | -1,499.90 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -38.92 | -- | -- | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -23.25m | 41.06m | 32.00 | -- | 2.45 | -- | -- | -0.107 | -0.107 | 0.00 | 0.0669 | 0.00 | -- | -- | 0.00 | -80.36 | -44.62 | -86.16 | -48.25 | -- | -- | -- | -2,344.60 | -- | -- | 0.0014 | -- | -65.62 | 55.71 | -9.26 | -- | -16.46 | -- |
| Immuneering Corp | 0.00 | -54.18m | 41.22m | 65.00 | -- | 0.5236 | -- | -- | -1.86 | -1.86 | 0.00 | 2.65 | 0.00 | -- | -- | 0.00 | -55.37 | -- | -58.58 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
| Hcw Biologics Inc | 3.93m | -27.39m | 41.23m | 45.00 | -- | 4.72 | -- | 10.50 | -0.7547 | -0.7547 | 0.1083 | 0.2311 | 0.1062 | -- | 6.79 | 87,258.22 | -74.07 | -- | -97.78 | -- | 29.61 | -- | -697.59 | -- | -- | -146.89 | 0.4863 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Dare Bioscience Inc | 2.82m | -28.87m | 41.45m | 23.00 | -- | -- | -- | 14.71 | -0.3175 | -0.3175 | 0.0308 | -0.1094 | 0.1299 | -- | 1.49 | 122,486.50 | -133.12 | -109.51 | -4,386.38 | -246.26 | 0.0579 | -- | -1,024.93 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| NKGen Biotech Inc | -100.00bn | -100.00bn | 41.56m | 63.00 | -- | -- | -- | -- | -- | -- | -- | -2.46 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -100.00 | -- | -210.06 | -- | -- | -- |
| Clene Inc. | 620.00k | -48.81m | 42.25m | 82.00 | -- | 9.91 | -- | 68.15 | -0.4764 | -0.4764 | 0.0053 | 0.0332 | 0.0146 | 2.11 | 9.76 | 7,560.98 | -114.91 | -39.43 | -233.02 | -47.32 | 78.71 | -- | -7,873.23 | -5,261.20 | 1.22 | -32.64 | 0.8641 | -- | 38.27 | -- | -65.47 | -- | -- | -- |
| NextCure Inc | 0.00 | -63.73m | 43.08m | 82.00 | -- | 0.4339 | -- | -- | -2.29 | -2.29 | 0.00 | 3.55 | 0.00 | -- | -- | 0.00 | -45.05 | -22.59 | -47.72 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| Eyenovia Inc | 8.78k | -32.44m | 43.53m | 57.00 | -- | 21.06 | -- | 4,957.58 | -0.7448 | -0.7448 | 0.0002 | 0.0384 | 0.0003 | -- | 0.008 | 154.04 | -116.94 | -80.31 | -190.14 | -117.70 | 0.00 | -- | -369,519.70 | -680.95 | 0.6645 | -16.03 | 0.8914 | -- | -- | -- | 2.68 | -- | 152.20 | -- |
| Ocuphire Pharma Inc | 19.01m | -11.30m | 43.55m | 14.00 | -- | 0.915 | -- | 2.29 | -0.4867 | -0.4867 | 0.8366 | 1.84 | 0.391 | -- | 4.52 | 1,357,929.00 | -23.24 | -58.31 | -25.89 | -65.94 | -- | -- | -59.44 | -137.92 | -- | -9.73 | 0.00 | -- | -52.20 | -- | -155.83 | -- | -- | -- |
| Aadi Bioscience Inc | 23.84m | -68.83m | 44.20m | 75.00 | -- | 0.4886 | -- | 1.85 | -2.55 | -2.55 | 0.8848 | 3.68 | 0.1692 | 0.6021 | 4.54 | 267,865.20 | -48.86 | -50.25 | -56.39 | -56.15 | 87.70 | -- | -288.72 | -473.97 | 4.86 | -- | 0.00 | -- | 60.06 | 3.85 | -8.68 | -- | 153.54 | -- |
Data as of May 31 2024. Currency figures normalised to Dare Bioscience Inc's reporting currency: US Dollar USD
6.40%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 3.42m | 3.40% |
| Geode Capital Management LLCas of 31 Mar 2024 | 989.31k | 0.98% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 762.90k | 0.76% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 381.29k | 0.38% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 247.71k | 0.25% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 183.30k | 0.18% |
| Citadel Securities LLCas of 31 Mar 2024 | 161.28k | 0.16% |
| T. Rowe Price International Ltd.as of 31 Mar 2024 | 125.90k | 0.13% |
| Founders Financial Securities LLCas of 31 Mar 2024 | 124.00k | 0.12% |
| Commonwealth Equity Services LLCas of 31 Mar 2024 | 45.93k | 0.05% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
